ArticleFrontiers in immunology2022

Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.

Changying Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.